ALLIANCE A031701

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

New, Temporarily Closed

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

NCT#03609216

Due to laboratory requirements necessitating the collection of additional information for genomic testing from all participating patients, A031701 is temporarily suspended, effective immediately, 04/11/19. An updated protocol and informed consent will be forthcoming.